In this article, we will discuss the 5 Best Pet Care Stocks to Buy for Consistent Recurring Revenue. For deeper discussion and analysis, read 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.
5. IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Short Percentage of Shares Outstanding: 2.76%
On May 26, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced the expansion of its Fecal Dx antigen testing platform to include detection of taeniid tapeworm species, including Taenia and Echinococcus. The enhanced testing capability is designed to identify a broader range of intestinal parasite infections and has been shown to detect up to twice as many infections earlier than fecal flotation alone. Beginning in late June, IDEXX Reference Laboratories customers across the United States and Canada will automatically receive taeniid tapeworm detection within Fecal Dx antigen testing panels and profiles at no additional cost, further strengthening the value of the company’s diagnostic offerings.
Previously, on May 19, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced that its SDMA renal biomarker will be integrated into Catalyst CLIPs, making comprehensive kidney function evaluation a standard component of the most used point-of-care chemistry profiles. Available to customers in the United States and Canada beginning in June, the integration is expected to improve access to advanced kidney health assessments and enable veterinarians to identify kidney function decline earlier without changing existing clinical workflows. Since launching the IDEXX SDMA Test in 2015, the company has performed approximately 119 million SDMA tests globally, demonstrating strong adoption and reinforcing the biomarker’s importance in veterinary kidney disease management.
Founded in 1983 and headquartered in Westbrook, Maine, IDEXX Laboratories, Inc. (NASDAQ:IDXX) deals in veterinary diagnostics, software, and water microbiology. It provides veterinarians with advanced in-clinic diagnostic instruments, rapid testing kits, and reference laboratory services that enable them to provide immediate, high-quality medical care to pets.
4. PetMed Express, Inc. (NASDAQ:PETS)
Short Percentage of Shares Outstanding: 2.48%
On June 2, PetMed Express, Inc. (NASDAQ:PETS) reported fourth-quarter revenue of $42.82 million, compared with $50.76 million in the prior-year period. Despite the year-over-year decline, management highlighted a sequential increase in quarterly net sales, signaling improving business momentum. Interim Chief Executive Officer and President Leslie Campbell stated that throughout 2026, the company focused on stabilizing its core operations and strengthening the foundation for long-term value creation through strategic, operational, and technology initiatives that reduced costs and enhanced efficiency. Management also emphasized plans to improve customer retention, expand business-to-business relationships, and leverage membership programs and white-label pharmacy fulfillment services, including its recently announced Master Services Agreement with Rural King.
On April 22, PetMed Express, Inc. (NASDAQ:PETS) announced a strategic partnership with Rural King to launch a new pet pharmacy platform, broadening access to prescription medications, preventative treatments, and pet healthcare products across Rural King’s retail and digital channels. Under the agreement, PetMeds will provide the pharmacy infrastructure, licensed pharmacists, and e-commerce capabilities required to support the offering. Management noted that the partnership aligns with the company’s growth strategy by extending its pharmacy platform to millions of pet owners who rely on Rural King for farm, ranch, and pet care products, while further advancing its mission of making quality pet healthcare more accessible and affordable nationwide.
Founded in 1996 and headquartered in Delray Beach, Florida, PetMed Express, Inc. (NASDAQ:PETS) is an online pet pharmacy and health retailer. The company markets and delivers FDA and EPA-approved prescription medications, over-the-counter flea and tick treatments, supplements, and specialized foods directly to pet owners nationwide, making it among the best pet care stocks to buy for consistent recurring revenue.
3. Oil-Dri Corporation of America (NYSE:ODC)
Short Percentage of Shares Outstanding: 2.21%
On June 8, Oil-Dri Corporation of America (NYSE:ODC) reported third-quarter revenue of $126.33 million, compared with $115.5 million in the prior-year period. President and CEO Daniel Jaffee highlighted that, following two quarters of difficult year-over-year comparisons, the company returned to growth with record third quarter consolidated net sales increasing 9%. Combined with disciplined expense management, the sales growth contributed to a 25% increase in net income despite ongoing inflationary pressures on the cost of goods sold. Management also noted that strong cash generation enabled the company to continue returning capital to shareholders and expressed confidence in achieving its annual plan and surpassing the previous year’s net income. However, geopolitical uncertainty and higher transportation and input costs remain potential headwinds.
On June 3, the board of directors of Oil-Dri Corporation of America (NYSE:ODC) approved a two-cent increase in the company’s quarterly cash dividend. The new dividend was raised to $0.225 per share of common stock and $0.168 per share of Class B stock, representing an approximate 10% increase for both share classes. The dividends will be payable on August 21 to shareholders of record as of August 7. In addition, the board authorized the repurchase of up to 500,000 shares of common stock, supplementing the shares already available under previous repurchase authorizations and demonstrating the company’s ongoing commitment to shareholder returns.
Founded in 1941 and headquartered in Chicago, Illinois, the Oil-Dri Corporation of America (NYSE:ODC) is a manufacturer of specialty sorbent products mined from specialty minerals. The company also produces widely used clay- and diatomaceous earth-based cat litter under major consumer brands like Cat’s Pride and Jonny Cat, alongside private-label offerings.
2. Aon plc (NYSE:AON)
Short Percentage of Shares Outstanding: 1.40%
On June 16, UBS lowered its price target on Aon plc (NYSE:AON) to $360 from $385 while maintaining a Neutral rating on the stock. The adjustment reflects the firm’s updated expectations for the company amid changing market conditions and a reassessment of the broader operating environment. While UBS continues to view the shares as fairly valued relative to their current risk-reward profile, the firm acknowledged Aon’s established position within the insurance brokerage industry and its ability to navigate evolving market dynamics. The revised target underscores a more measured outlook but does not materially alter the company’s long-term strategic positioning.
A day earlier, on June 15, Piper Sandler reduced its price target on Aon plc (NYSE:AON) to $355 from $360 while reiterating an Overweight rating on the shares. The firm identified Aon as its weekly focus idea, highlighting the company’s resilience despite the challenging conditions facing insurance brokers. According to Piper Sandler, Aon is not entirely immune to industry headwinds, but it is expected to outperform many competitors due to the strength and diversity of its business model. The firm further described Aon as an attractive defensive investment within the sector, citing its ability to generate stable results and adapt to changing market conditions.
Founded in 1982, Aon plc (NYSE:AON) is a leading professional services firm headquartered in Dublin, Ireland. The company provides a broad range of risk management, insurance, and reinsurance brokerage, and human capital consulting services to clients worldwide. In addition to its core offerings, Aon works with insurance providers to make customizable pet insurance solutions available, helping pet owners manage costs associated with accidents, illnesses, and routine veterinary care.
1. Lemonade, Inc. (NYSE:LMND)
Short Percentage of Shares Outstanding: 0.01%
On June 11, Lemonade, Inc. (NYSE:LMND) announced that its renters’ insurance product is now available in Montana, further expanding the company’s geographic footprint in the United States. Management stated that the launch aligns with Lemonade’s mission of simplifying the insurance experience through technology-driven solutions, providing Montana residents with easier access to renters insurance through the company’s digital platform. The expansion reflects Lemonade’s continued efforts to grow its customer base and increase market penetration across additional states.
On June 8, TD Cowen raised its price target on Lemonade, Inc. (NYSE:LMND) to $55 from $33 while maintaining a Hold rating on the shares. The substantial increase in the target price reflects a more favorable outlook on the company’s prospects and suggests improved confidence in its operational performance and growth trajectory, even as the firm remains neutral on the stock.
Founded in 2015 and headquartered in New York, NY, Lemonade, Inc. (NYSE:LMND) is a digital insurance company that utilizes artificial intelligence and behavioral economics to replace traditional brokers and paperwork with seamless online apps and automated claims. The company also offers specialized pet health insurance policies that cover diagnostics, procedures, and medications for dogs and cats.
While we acknowledge the potential of LMND as a pet care stock to buy for consistent recurring revenue, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LMND and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 7 Best “Land Owner” Stocks to Buy for Hard Asset Value and Top 10 Stocks That Members of Congress Own.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
